IMF Supports the Bipartisan Cancer Drug Parity Act for Improved Access to Cancer Treatments
The International Myeloma Foundation (IMF) strongly endorses the Cancer Drug Parity Act, co-led by Representatives Glenn Grothman, Suzanne Bonamici, Gus Bilirakis, Joe Morelle, Brian Fitzpatrick, Brian Higgins, and Doris Matsui. This crucial legislation aims to lower costs for cancer patients by ensuring health insurers provide equal coverage for oral cancer treatments, compared to traditional intravenous treatments. Oral treatments offer convenience and effectiveness but have been costly for patients. The IMF believes this bill is a significant step towards increasing access to life-saving treatments. It aligns with the IMF's mission to prioritize affordability and equal access to anticancer treatments and will empower individuals battling cancer and their healthcare providers to make informed treatment decisions without undue financial strain. The IMF fully supports this legislation and commends the bipartisan efforts to make cancer care more affordable, accessible, and manageable, ultimately saving lives.